|

NX-5948 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Bexobrutideg

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • Nurix Therapeutics, Inc.2

Indications

  • Small Lymphocytic Lymphoma (SLL)2
  • Chronic Lymphocytic Leukemia (CLL)2
  • Cancer2
  • Secondary Central Nervous System Lymphoma (SCNSL)1
  • Waldenstrom Macroglobulinemia (WM)1

Duarte, California1 trial

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope

Phase 1

Denver, Colorado1 trial

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Colorado Blood Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.